Oxcarbazepine - Revision history

Danbot: Add verified PubMed references (PMIDs 10845729, 30000302)

2026-03-22T10:44:43Z

Add verified PubMed references (PMIDs 10845729, 30000302)

← Revisión anterior		Revisión del 10:44 22 mar 2026
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type: [[Antiepileptics]]		*Type: [[Antiepileptics]]<ref>Shorvon S. Oxcarbazepine: a review. Seizure. 2000 Mar;9(2):75-9. PMID 10845729</ref>
	*Dosage Forms: 150,300,600mg; 300mg/5 mL		*Dosage Forms: 150,300,600mg; 300mg/5 mL
	*Routes of Administration: PO		*Routes of Administration: PO
Línea 70:		Línea 70:
	*caution in elderly patients		*caution in elderly patients
	*caution in pregnancy		*caution in pregnancy
	*caution if hyponatremia		*caution if hyponatremia<ref>. Oxcarbazepine. 2006. PMID 30000302</ref>
	*caution if renal impairment		*caution if renal impairment
	*caution if depression or history		*caution if depression or history

Elcatracho: /* See Also */

2021-03-08T04:10:53Z

Elcatracho: /* See Also */

2021-03-08T04:10:19Z

Elcatracho: /* Administration */

2021-03-08T04:09:36Z

Administration

← Revisión anterior		Revisión del 04:09 8 mar 2021
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type: [[Antiepileptics]]		*Type: [[Antiepileptics]]
	*Dosage Forms: 150,300,~~600~~; ~~300~~/5 mL		*Dosage Forms: 150,300,600mg; 300mg/5 mL
	*Routes of Administration: PO		*Routes of Administration: PO
	*Common Trade Names: Trileptal		*Common Trade Names: Trileptal

ClaireLewis at 00:49, 23 September 2019

2019-09-23T00:49:42Z

← Revisión anterior		Revisión del 00:49 23 sep 2019
Línea 1:		Línea 1:
	==Administration==		==Administration==
	*Type: ~~anti epileptic~~		*Type: [[Antiepileptics]]
	*Dosage Forms: 150,300,600; 300/5 mL		*Dosage Forms: 150,300,600; 300/5 mL
	*Routes of Administration: PO		*Routes of Administration: PO
Línea 137:		Línea 137:
	==References==		==References==
	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:Neurology]]
	epocrates		epocrates

Mholtz: Text replacement - " bid " to " BID "

2017-07-07T10:14:01Z

Text replacement - " bid " to " BID "

← Revisión anterior		Revisión del 10:14 7 jul 2017
Línea 23:		Línea 23:
	====adjunct therapy====		====adjunct therapy====
	*2-3 yo		*2-3 yo
	**Dose: 60mg/kg/day PO divided bid; Start: 8-10mg/kg/day PO divided ~~bid~~ up to 600mg/day, increase dose over 2-4wk; Max: 60mg/kg/day		**Dose: 60mg/kg/day PO divided bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase dose over 2-4wk; Max: 60mg/kg/day
	**may start 16-20mg/kg/day PO divided ~~bid~~ in patients <20 kg		**may start 16-20mg/kg/day PO divided BID in patients <20 kg
	*4-16 yo, 20-29 kg		*4-16 yo, 20-29 kg
	**Dose: 600mg PO bid; Start: 8-10mg/kg/day PO divided ~~bid~~ up to 600mg/day, increase to target dose over 2wk		**Dose: 600mg PO bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase to target dose over 2wk
	*4-16 yo, >39 kg		*4-16 yo, >39 kg
	**Dose: 900mg PO bid; Start: 8-10mg/kg/day PO divided ~~bid~~ up to 600mg/day, increase to target dose over 2wk		**Dose: 900mg PO bid; Start: 8-10mg/kg/day PO divided BID up to 600mg/day, increase to target dose over 2wk

	====monotherapy====		====monotherapy====

Rossdonaldson1: Text replacement - "hx" to "history"

2016-07-31T01:04:11Z

Text replacement - "hx" to "history"

← Revisión anterior		Revisión del 01:04 31 jul 2016
Línea 72:		Línea 72:
	*caution if hyponatremia		*caution if hyponatremia
	*caution if renal impairment		*caution if renal impairment
	*caution if depression or hx		*caution if depression or history

	==Adverse Reactions==		==Adverse Reactions==

Neil.m.young: Text replacement - "0 mg" to "0mg"

2016-07-21T04:28:06Z

Text replacement - "0 mg" to "0mg"

← Revisión anterior		Revisión del 04:28 21 jul 2016
Línea 7:		Línea 7:
	==Adult Dosing==		==Adult Dosing==
	===Partial seizures===		===Partial seizures===
	*adjunct treatment: Dose: ~~600 mg~~ PO bid; Start: ~~300 mg~~ PO bid, increase by up to ~~600 mg~~/day qwk; Max: ~~2400 mg~~/day;		*adjunct treatment: Dose: 600mg PO bid; Start: 300mg PO bid, increase by up to 600mg/day qwk; Max: 2400mg/day;
	*conversion to monotherapy: Dose: ~~1200 mg~~ PO bid; Start: ~~300 mg~~ PO bid, increase by up to ~~600 mg~~/day qwk; Max: ~~2400 mg~~/day; discontinue concomitant anticonvulsants over 3-6wk; taper dose gradually to discontinue		*conversion to monotherapy: Dose: 1200mg PO bid; Start: 300mg PO bid, increase by up to 600mg/day qwk; Max: 2400mg/day; discontinue concomitant anticonvulsants over 3-6wk; taper dose gradually to discontinue
	*initial monotherapy: Dose: ~~600 mg~~ PO bid; Start: ~~300 mg~~ PO bid, increase by ~~300 mg~~/day q3 days; Max: ~~2400 mg~~/day		*initial monotherapy: Dose: 600mg PO bid; Start: 300mg PO bid, increase by 300mg/day q3 days; Max: 2400mg/day

	===Trigeminal neuralgia===		===Trigeminal neuralgia===
	*450-~~1200 mg~~ PO bid		*450-1200mg PO bid
	*Start: ~~300 mg~~ PO bid, may increase by ~~600 mg~~/day qwk		*Start: 300mg PO bid, may increase by 600mg/day qwk

	===Bipolar disorder===		===Bipolar disorder===
	*600-~~1200 mg~~ PO bid		*600-1200mg PO bid
	*Start: ~~300 mg~~ PO bid, increase by ~~300 mg~~/day q3 days or by ~~600 mg~~/day qwk		*Start: 300mg PO bid, increase by 300mg/day q3 days or by 600mg/day qwk

	==Pediatric Dosing==		==Pediatric Dosing==
Línea 23:		Línea 23:
	====adjunct therapy====		====adjunct therapy====
	*2-3 yo		*2-3 yo
	**Dose: ~~60 mg~~/kg/day PO divided bid; Start: 8-~~10 mg~~/kg/day PO divided bid up to ~~600 mg~~/day, increase dose over 2-4wk; Max: ~~60 mg~~/kg/day		**Dose: 60mg/kg/day PO divided bid; Start: 8-10mg/kg/day PO divided bid up to 600mg/day, increase dose over 2-4wk; Max: 60mg/kg/day
	**may start 16-~~20 mg~~/kg/day PO divided bid in patients <20 kg		**may start 16-20mg/kg/day PO divided bid in patients <20 kg
	*4-16 yo, 20-29 kg		*4-16 yo, 20-29 kg
	**Dose: ~~600 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid up to ~~600 mg~~/day, increase to target dose over 2wk		**Dose: 600mg PO bid; Start: 8-10mg/kg/day PO divided bid up to 600mg/day, increase to target dose over 2wk
	*4-16 yo, >39 kg		*4-16 yo, >39 kg
	**Dose: ~~900 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid up to ~~600 mg~~/day, increase to target dose over 2wk		**Dose: 900mg PO bid; Start: 8-10mg/kg/day PO divided bid up to 600mg/day, increase to target dose over 2wk

	====monotherapy====		====monotherapy====
	*4-16 yo, 20-24 kg		*4-16 yo, 20-24 kg
	**Dose: 300-~~450 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to ~~10 mg~~/kg/day qwk if conversion to monotherapy		**Dose: 300-450mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 25-34 kg		*4-16 yo, 25-34 kg
	**Dose: 450-~~600 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to ~~10 mg~~/kg/day qwk if conversion to monotherapy		**Dose: 450-600mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 35-44 kg		*4-16 yo, 35-44 kg
	**Dose: 450-~~750 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to ~~10 mg~~/kg/day qwk if conversion to monotherapy		**Dose: 450-750mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 45-49 kg		*4-16 yo, 45-49 kg
	**Dose: 600-~~750 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to ~~10 mg~~/kg/day qwk if conversion to monotherapy		**Dose: 600-750mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 50-59 kg		*4-16 yo, 50-59 kg
	**Dose: 600-~~900 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to ~~10 mg~~/kg/day qwk if conversion to monotherapy		**Dose: 600-900mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 60-69 kg		*4-16 yo, 60-69 kg
	**Dose: 600-~~1050 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to ~~10 mg~~/kg/day qwk if conversion to monotherapy		**Dose: 600-1050mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, >70 kg		*4-16 yo, >70 kg
	**Dose: 750-~~1050 mg~~ PO bid; Start: 8-~~10 mg~~/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to ~~10 mg~~/kg/day qwk if conversion to monotherapy		**Dose: 750-1050mg PO bid; Start: 8-10mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk

Línea 57:		Línea 57:
	*[[Lactation risk categories\|Lactation risk]]: safety unknown		*[[Lactation risk categories\|Lactation risk]]: safety unknown
	===Renal Dosing===		===Renal Dosing===
	*Adult: CrCl <30: start ~~150 mg~~ bid; HD/PD: no supplement; Info: titrate dose slowly until response		*Adult: CrCl <30: start 150mg bid; HD/PD: no supplement; Info: titrate dose slowly until response
	*Pediatric: CrCl <30: decrease start dose 50%, max start dose ~~300 mg~~/24h; HD/PD: no supplement; Info: titrate dose slowly until response		*Pediatric: CrCl <30: decrease start dose 50%, max start dose 300mg/24h; HD/PD: no supplement; Info: titrate dose slowly until response
	===Hepatic Dosing===		===Hepatic Dosing===
	*Adult: mild-mod impairment: no adjustment; severe impairment: not defined		*Adult: mild-mod impairment: no adjustment; severe impairment: not defined

Neil.m.young: Text replacement - "5 mg" to "5mg"

2016-07-20T02:26:12Z

Text replacement - "5 mg" to "5mg"

← Revisión anterior		Revisión del 02:26 20 jul 2016
Línea 32:		Línea 32:
	====monotherapy====		====monotherapy====
	*4-16 yo, 20-24 kg		*4-16 yo, 20-24 kg
	**Dose: 300-450 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by ~~5 mg~~/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 300-450 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 25-34 kg		*4-16 yo, 25-34 kg
	**Dose: 450-600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by ~~5 mg~~/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 450-600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 35-44 kg		*4-16 yo, 35-44 kg
	**Dose: 450-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by ~~5 mg~~/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 450-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 45-49 kg		*4-16 yo, 45-49 kg
	**Dose: 600-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by ~~5 mg~~/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 600-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 50-59 kg		*4-16 yo, 50-59 kg
	**Dose: 600-900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by ~~5 mg~~/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 600-900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 60-69 kg		*4-16 yo, 60-69 kg
	**Dose: 600-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by ~~5 mg~~/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 600-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, >70 kg		*4-16 yo, >70 kg
	**Dose: 750-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by ~~5 mg~~/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 750-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk

ClaireLewis at 20:38, 15 July 2016

2016-07-15T20:38:33Z

← Revisión anterior		Revisión del 20:38 15 jul 2016
Línea 7:		Línea 7:
	==Adult Dosing==		==Adult Dosing==
	===Partial seizures===		===Partial seizures===
	*adjunct treatment: Dose: 600 mg PO bid; Start: 300 mg PO bid, ~~incr.~~ by up to 600 mg/day qwk; Max: 2400 mg/day;		*adjunct treatment: Dose: 600 mg PO bid; Start: 300 mg PO bid, increase by up to 600 mg/day qwk; Max: 2400 mg/day;
	*conversion to monotherapy: Dose: 1200 mg PO bid; Start: 300 mg PO bid, ~~incr.~~ by up to 600 mg/day qwk; Max: 2400 mg/day; discontinue concomitant anticonvulsants over 3-6wk; taper dose gradually to discontinue		*conversion to monotherapy: Dose: 1200 mg PO bid; Start: 300 mg PO bid, increase by up to 600 mg/day qwk; Max: 2400 mg/day; discontinue concomitant anticonvulsants over 3-6wk; taper dose gradually to discontinue
	*initial monotherapy: Dose: 600 mg PO bid; Start: 300 mg PO bid, ~~incr.~~ by 300 mg/day q3 days; Max: 2400 mg/day		*initial monotherapy: Dose: 600 mg PO bid; Start: 300 mg PO bid, increase by 300 mg/day q3 days; Max: 2400 mg/day

	===Trigeminal neuralgia===		===Trigeminal neuralgia===
	*450-1200 mg PO bid		*450-1200 mg PO bid
	*Start: 300 mg PO bid, may ~~incr.~~ by 600 mg/day qwk		*Start: 300 mg PO bid, may increase by 600 mg/day qwk

	===Bipolar disorder===		===Bipolar disorder===
	*600-1200 mg PO bid		*600-1200 mg PO bid
	*Start: 300 mg PO bid, ~~incr.~~ by 300 mg/day q3 days or by 600 mg/day qwk		*Start: 300 mg PO bid, increase by 300 mg/day q3 days or by 600 mg/day qwk

	==Pediatric Dosing==		==Pediatric Dosing==
Línea 23:		Línea 23:
	====adjunct therapy====		====adjunct therapy====
	*2-3 yo		*2-3 yo
	**Dose: 60 mg/kg/day PO divided bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, ~~incr.~~ dose over 2-4wk; Max: 60 mg/kg/day		**Dose: 60 mg/kg/day PO divided bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, increase dose over 2-4wk; Max: 60 mg/kg/day
	**may start 16-20 mg/kg/day PO divided bid in patients <20 kg		**may start 16-20 mg/kg/day PO divided bid in patients <20 kg
	*4-16 yo, 20-29 kg		*4-16 yo, 20-29 kg
	**Dose: 600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, ~~incr.~~ to target dose over 2wk		**Dose: 600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, increase to target dose over 2wk
	*4-16 yo, >39 kg		*4-16 yo, >39 kg
	**Dose: 900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, ~~incr.~~ to target dose over 2wk		**Dose: 900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid up to 600 mg/day, increase to target dose over 2wk

	====monotherapy====		====monotherapy====
	*4-16 yo, 20-24 kg		*4-16 yo, 20-24 kg
	**Dose: 300-450 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, ~~incr.~~ by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 300-450 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 25-34 kg		*4-16 yo, 25-34 kg
	**Dose: 450-600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, ~~incr.~~ by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 450-600 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 35-44 kg		*4-16 yo, 35-44 kg
	**Dose: 450-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, ~~incr.~~ by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 450-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 45-49 kg		*4-16 yo, 45-49 kg
	**Dose: 600-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, ~~incr.~~ by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 600-750 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 50-59 kg		*4-16 yo, 50-59 kg
	**Dose: 600-900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, ~~incr.~~ by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 600-900 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, 60-69 kg		*4-16 yo, 60-69 kg
	**Dose: 600-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, ~~incr.~~ by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 600-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk
	*4-16 yo, >70 kg		*4-16 yo, >70 kg
	**Dose: 750-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, ~~incr.~~ by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy		**Dose: 750-1050 mg PO bid; Start: 8-10 mg/kg/day PO divided bid, increase by 5 mg/kg/day q3 days if initial monotherapy or by up to 10 mg/kg/day qwk if conversion to monotherapy
	**Discontinue concomitant anticonvulsants over 3-6wk		**Discontinue concomitant anticonvulsants over 3-6wk

Línea 58:		Línea 58:
	===Renal Dosing===		===Renal Dosing===
	*Adult: CrCl <30: start 150 mg bid; HD/PD: no supplement; Info: titrate dose slowly until response		*Adult: CrCl <30: start 150 mg bid; HD/PD: no supplement; Info: titrate dose slowly until response
	*Pediatric: CrCl <30: ~~decr.~~ start dose 50%, max start dose 300 mg/24h; HD/PD: no supplement; Info: titrate dose slowly until response		*Pediatric: CrCl <30: decrease start dose 50%, max start dose 300 mg/24h; HD/PD: no supplement; Info: titrate dose slowly until response
	===Hepatic Dosing===		===Hepatic Dosing===
	*Adult: mild-mod impairment: no adjustment; severe impairment: not defined		*Adult: mild-mod impairment: no adjustment; severe impairment: not defined
Línea 129:		Línea 129:

	==Mechanism of Action==		==Mechanism of Action==
	blocks voltage-sensitive Na channels, stabilizes neural membranes, inhibits repetitive firing, and ~~decr.~~ synaptic impulse propagation		blocks voltage-sensitive Na channels, stabilizes neural membranes, inhibits repetitive firing, and decreases synaptic impulse propagation

	==Comments==		==Comments==

← Revisión anterior		Revisión del 04:10 8 mar 2021
Línea 136:		Línea 136:
	*[[Seizures]]		*[[Seizures]]
	*[[Anticonvulsants]]		*[[Anticonvulsants]]
	*[[Anticonvulsant toxicity]]

	==References==		==References==

← Revisión anterior		Revisión del 04:10 8 mar 2021
Línea 134:		Línea 134:

	==See Also==		==See Also==
			*[[Seizures]]
			*[[Anticonvulsants]]
			*[[Anticonvulsant toxicity]]

	==References==		==References==